ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Strong Buy

<< Previous

Bullboard Posts

Next >>

Comment by FarmerBettyon Jun 16, 2022 9:45am

143 Views

Post# 34760919

RE:RE:RE:Strong Buy

Interesting Promis doesn't communicate that one of the Boston group is involved on a nearly daily basis and how do you know this?
This is typical of Promis withholding critical information and engineering the market to where it is. No question the Boston group has been privy to different informatiion than the general public.
All the US institutional investors have access to markets Promis currently trades in, the consolidation of shares of shares if it happens is designed to squeeze out smaller investors which will happen. Google it. Not producing a deal with Pharma will confirm the fix is in

<< Previous

Bullboard Posts

Next >>

Mullen Group's Robust Case for Value, Part 1: Less-than-Truckload